pharmaphorum

SEPTEMBER 24, 2020

An artificial intelligence-powered diagnostic for autism spectrum disorder (ASD), developed by Cognoa, has met all its objectives in a pivotal trial and will be filed for approval with the FDA. It’s reported that parents can often spot the early signs of developmental problems within 18 months.

Behavioural Health 134

Behavioural Health Doctor Doctors Development 134

pharmaphorum

JANUARY 27, 2022

“I observed that my colleagues who were working to develop and validate various clinical applications of virtual reality technology had no venue to publish their work in a way that would reach other scientists grappling with the same issues and constraints,” Greenleaf said.

Production 142

Production Development Behavioural Health Research 142

pharmaphorum

APRIL 25, 2022

Aaron Gani, founder and CEO of BehaVR, and Krys Zaluski, director of business development, digital health at Sumitomo Dainippon Pharma, discuss their groundbreaking partnership to develop and commercialise digital therapeutics (DTx) products. . Gani started BehaVR in 2016 to create DTx for mental and behavioural health.

Behavioural Health 105

Behavioural Health Production Clinical Trials Clinical Trials 105

pharmaphorum

JANUARY 26, 2021

There is an opportunity to address this at scale with digital tools and techniques, and expand support into just about any therapeutic area through the holistic integration of mental and behavioural health solutions that improve patient care. Services to manage and make sense of the health data explosion.

Clinical Trials 141

Clinical Trials Clinical Trials Sales Life Science 141

pharmaphorum

DECEMBER 16, 2022

Digital therapeutics company Cognoa, which focuses on paediatric behavioural health, announced the appointment of Dr Sharief Taraman as its new CEO. Optibrium, another software developer in the AI drug discovery space, has appointed Ian Smith as its new chief technology officer. McKinnell, Jr. to support the company’s growth.

Behavioural Health 52

Behavioural Health Reagent Gene Therapy Production 52

pharmaphorum

DECEMBER 20, 2022

Boehringer Ingelheim (BI) and Click Therapeutics have announced they are expanding their collaboration to develop and commercialise a second prescription-based digital therapeutic (PDT) that will provide additional treatment options to those living with schizophrenia. Schizophrenia is one of the 15 leading causes of disability worldwide.

Behavioural Health 52

Behavioural Health Development Research 52

pharmaphorum

MARCH 21, 2022

In a crowd of 200 attendees, guests included medical XR start-ups, hospitals, and research universities from around the globe. In 2021, the behavioural health company and Sumitomo Dainippon Pharma Co.

Behavioural Health 98

Behavioural Health Pharma Companies Life Science FDA Approval 98